Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
Eur Stroke J. 2023 Dec;8(4):932-941. doi: 10.1177/23969873231196381. Epub 2023 Aug 29.
The benefit of endovascular treatment in large anterior circulation ischaemic strokes with low ASPECTS score (<6) is uncertain. Recent randomised studies have demonstrated the benefit of endovascular treatment (EVT) in large ischaemic strokes. The present meta-analysis aims to assess the combined effect of these studies on efficacy and safety of endovascular treatment in this group of patients.
We conducted a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Databases MEDLINE, PubMed, EMBASE, SCOPUS, Google Scholar, Tripdatabase were searched for randomised controlled trials with at least 50 participants from inception until February 16, 2023. The primary efficacy outcome analysed was the relative risk of functional independence defined as mRS - 0-2 at 90 days. Secondary efficacy outcomes included early neurological improvement, death due to any cause at 90 days and proportion of patients requiring decompressive hemicraniectomy. The primary safety outcome was the risk of developing symptomatic intracerebral haemorrhage (sICH).
A total of three studies (RESCUE Japan-LIMIT, SELECT 2 and ANGEL ASPECTS) involving 1011 patients; 510 in the EVT arm and 501 in the medical management (MM) arm met the defined criteria (ASPECTS-3-5). The combined RR for the primary outcome of mRS 0-2 was 2.53 [1.84-3.47] ( = <0.0001) favouring EVT over MM. The primary safety outcome of sICH was not significant in the EVT arm with a combined RR of 1.84 [0.94-3.60] ( = 0.5157). Mortality rates were similar in both arms (26.67% in EVT arm vs 27.94% in MM arm) with a combined RR of 0.95 [0.78; 1.16] ( = 1.000).
In patients with Large vessel occlusion (LVO) and low ASPECTS (3-5), EVT was associated with higher likelihood of achieving functional independence and early neurologic improvement but did not provide any mortality benefit.
低 ASPECTS 评分(<6)的大前循环缺血性卒中的血管内治疗获益尚不确定。最近的随机研究表明,血管内治疗(EVT)对大缺血性卒中有益。本荟萃分析旨在评估这些研究对这组患者血管内治疗的疗效和安全性的综合影响。
我们根据系统评价和荟萃分析的首选报告项目进行了系统评价和荟萃分析。从成立到 2023 年 2 月 16 日,我们在 MEDLINE、PubMed、EMBASE、SCOPUS、Google Scholar、Tripdatabase 等数据库中搜索了至少 50 名参与者的随机对照试验。主要疗效结局分析为 90 天 mRS 0-2 的功能独立性的相对风险。次要疗效结局包括早期神经改善、90 天任何原因导致的死亡以及需要去骨瓣减压的患者比例。主要安全性结局为症状性颅内出血(sICH)的风险。
共有三项研究(RESCUE Japan-LIMIT、SELECT 2 和 ANGEL ASPECTS)涉及 1011 名患者;EVT 组 510 例,药物治疗(MM)组 501 例符合定义标准(ASPECTS-3-5)。mRS 0-2 的主要结局的合并 RR 为 2.53 [1.84-3.47]( = <0.0001),表明 EVT 优于 MM。EVT 组的主要安全性结局 sICH 不显著,合并 RR 为 1.84 [0.94-3.60]( = 0.5157)。两组死亡率相似(EVT 组 26.67%,MM 组 27.94%),合并 RR 为 0.95 [0.78;1.16]( = 1.000)。
在大血管闭塞(LVO)和低 ASPECTS(3-5)的患者中,EVT 与更高的功能独立性和早期神经改善的可能性相关,但没有提供任何死亡率获益。